Tibotec unveils results of experimental HIV drug

Johnson & Johnson (NYSE: JNJ) unit Tibotec Pharmaceuticals has reported results from two pivotal Phase III trials comparing its investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) with efavirenz. Each drug was administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults. And while the experimental HIV drug worked as well as efavirenz with fewer side effects, almost twice as many...